Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Atebimetinib |
| Trade Name | |
| Synonyms | IMM 1-104|IMM1-104|IMM-1-104 |
| Drug Descriptions |
Atebimetinib allosterically inhibits MEK1 and MEK2, potentially resulting in decreased downstream Erk1/2 activation and inhibition of tumor growth (PMID: 42478961). |
| DrugClasses | MEK inhibitor (Pan) 27 MEK1 Inhibitor 28 MEK2 Inhibitor 26 |
| CAS Registry Number | 2669009-92-9 |
| NCIT ID | C192810 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Atebimetinib | Atebimetinib | 2 | 1 |
| Atebimetinib + Dabrafenib | Atebimetinib Dabrafenib | 0 | 1 |
| Atebimetinib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Atebimetinib Fluorouracil Irinotecan Leucovorin Oxaliplatin | 0 | 1 |
| Atebimetinib + Gemcitabine + Nab-paclitaxel | Atebimetinib Gemcitabine Nab-paclitaxel | 0 | 2 |
| Atebimetinib + Pembrolizumab | Atebimetinib Pembrolizumab | 0 | 1 |